These independent CME/CE activities are supported by educational grants from Genentech BioOncology

Recurrent Ovarian Cancer
Program Series
  1. Course List
faculty image
Bradley J. Monk, MD, FACOG, FACS
  • Associate Professor
  • Division of Gynecologic Oncology
  • Department of Obstetrics and Gynecology
  • Chao Family Comprehensive Cancer Center
  • University of California, Irvine
  • Orange, California
  • Projects In Knowledge is pleased to present Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer - €”Program Series. Featuring the very latest state-of-the-science information about practical therapeutic approaches for clinicians interested in improving outcomes in their patients with ovarian cancer - this free online program series offers CME, CE, and CPE credit. Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer - Program Series is building a community of experts to help you provide your patients with the best treatment outcome possible.
  • Evaluate the benefits and limitations of markers in assessing the prognosis of patients with ovarian cancer and monitoring the efficacy of targeted therapy treatment and management of this disease.
  • Assess overall goals of therapy in order to select optimal treatment that improves patient outcomes.
  • Formulate personalized, successful treatment regimens with appropriate targeted therapies, alone or in combination with other agents, for patients with ovarian cancer, including platinum-sensitive and platinum-resistant, based on an analysis of the MOA, efficacy and safety of these therapies, and considerations for their optimal use.
  • Distinguish side effects of various targeted therapies in contrast to those of chemotherapeutic agents to optimally manage and maintain patients on therapy for improved outcomes.
  • Analyze those patients with ovarian cancer who would benefit most from and who are candidates for treatment with targeted therapies, to improve response to treatment.
    • Experimental Regimens
      • Frontline use of targeted therapies
      • Combination bevacizumab and chemotherapy regimens
      • Maintenance bevacizumab therapy
      • Combination multi-targeted TKI and chemotherapy regimens
      • Olaparib in BRCA-deficient tumors
      • Olaparib maintenance therapy
      • Farletuzumab/chemotherapy combination treatment
      • Bevacizumab/everolimus combination therapy
      • Pertuzumab/chemotherapy combination therapy
    • Use of HER3 biomarker in pertuzumab therapy
    • Managing the side effects of targeted therapies
    • Role of angiogenesis in ovarian cancer
    • PDGF and FGF in angiogenesis
    • Classes of anti-angiogenic agents
    • Multi-targeted anti-angiogenic TKIs
    • Role of PARP in DNA repair
    • PARP inhibitors
    • Anti-folates
    • mTOR inhibitors
    • HER2 inhibitors
    • Prognostic/predictive factors
    • Unique toxicities of targeted agents
    • Toxicities specific to ovarian cancer patients

    Target Audience

    This activity is designed for gynecologic oncologists, medical oncologists, and other healthcare professionals who are involved in the care of patients with recurrent ovarian cancer.


    Activity Goal

    The goal of CME/CE activity is to provide up-to-date information on emerging new targeted therapy treatment strategies for the management of patients with ovarian cancer, including platinum-sensitive and platinum-resistant, to incorporate into best practices in the office setting to improve patient outcomes.